Clinical Trials Logo

Clinical Trial Summary

Multidrug-resistant tuberculosis (MDR-TB) is tuberculosis (TB) that is resistant to at least isoniazid and rifampicin, the two most important anti-TB drugs. It occurs in 3.6% of newly diagnosed TB patients in the world and 17% of patients who have been previously treated. In 2017, approximately 600,000 people were estimated to have acquired MDR-TB. However, only 25% of persons with MDR-TB were diagnosed and started on treatment, reflecting inadequate diagnostic capacity and lack of TB treatment capacity. In this multicenter, randomized, partially blinded, four-arm, phase 2 study, the investigators will examine the efficacy and safety of an all-oral regimen of bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine given for 16, 24, 32 or 40 weeks


Clinical Trial Description

Multidrug-resistant tuberculosis (MDR-TB) is tuberculosis that is resistant to at least isoniazid and rifampicin, the two most important drugs in treating TB. In 2017, approximately 558,000 new people were estimated to have developed MDR-TB, and 8.5% of the cases had extensively drug-resistant tuberculosis (XDR-TB).(1) Current WHO-endorsed MDR-TB treatment regimens take 9-20 months to complete and are associated with substantial toxicity, including deafness from injectable agents, hepatitis from pyrazinamide and severe neuropathy from linezolid. Given the long duration and toxicities of MDR-TB regimens, it is perhaps not surprising that WHO reports that only 25% of patients with MDR-TB are enrolled into WHO-endorsed treatment regimens. Thus, there is an urgent need for shorter, less toxic treatments for MDR-TB. This proposal will determine the efficacy, safety, tolerability and optimal duration of a novel, all oral MDR-TB treatment regimen while addressing three major challenges with innovations that have the potential to transform future trials. The proposed DRAMATIC (Duration Randomized Anti-MDR-TB And Tailored Intervention Clinical) Trial is a multicenter, randomized, partially blinded, four-arm, phase 2 trial that will examine an injectable- and pyrazinamide-sparing regimen of bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine. The DRAMATIC regimen limits the administration of linezolid to the initial 8 weeks of treatment, the window before linezolid-related neuropathy occurs. Animal and human studies provide evidence for the potential efficacy of this 5-drug regimen, but the optimal duration of treatment remains uncertain.(2-4) Primary Objectives: 1. Describe the relationship between the duration of the experimental regimen and the proportion of participants with sustained cure at 76 weeks after randomization without treatment failure or relapse. 2. Describe the relationship between baseline prognostic risk strata and sustained cure at 76 weeks after randomization without treatment failure or relapse. 3. Evaluate the association between novel biologic markers and sustained cure at 76 weeks after randomization without treatment failure or relapse. Secondary Objectives: 4. Identify the shortest duration of the study regimen that has acceptable safety and efficacy for a Phase 3 clinical trial of the DRAMATIC regimen for treatment of MDR-TB. 5. Describe the frequency, magnitude, time course of and risk factors for QTc prolongation associated with the study regimen. 6. Demonstrate the feasibility and efficiency of implementing the new duration-randomized design in a multi-centre randomized trial of drug-resistant TB. 7. Determine if time to sputum culture conversion predicts optimal duration of treatment when stratified by extent of disease. 8. Describe the relationship between the duration of the experimental regimen and the proportion of participants with sustained cure at 104 weeks after randomization without treatment failure or relapse. 9. Assess vital status at 132 weeks post randomization. Development of a shorter, better-tolerated treatment regimen will greatly enhance the ability of TB control programs to treat the growing number of patients. The DRAMATIC Trial will employ an innovative and efficient new design to establish a robust, nontoxic MDR-TB treatment regimen and identify the minimal duration for which it needs to be administered. These results will speed the process of moving forward to a confirmatory phase 3 clinical trial and increase the likelihood that such a trial is successful. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03828201
Study type Interventional
Source Boston University
Contact Pawandeep Kaur, MPH
Phone (617) 358-2421
Email kaurp@bu.edu
Status Recruiting
Phase Phase 2
Start date June 7, 2022
Completion date May 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05871489 - Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Active, not recruiting NCT04179500 - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers Phase 2
Completed NCT03086486 - Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Phase 3
Completed NCT01201941 - Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru N/A
Not yet recruiting NCT06441006 - Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Phase 3
Completed NCT03303963 - DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Completed NCT02413931 - Nosocomial Transmission of MDR-TB in Bucharest, Romania
Recruiting NCT05306223 - A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China Phase 4
Completed NCT02573350 - A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Phase 2
Completed NCT02597621 - Biomarkers for Therapy Response in Drug-resistant Tuberculosis
Recruiting NCT05555303 - Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis Phase 2
Recruiting NCT01212003 - Training Protocol on the Natural History of Tuberculosis
Terminated NCT03237182 - The Individualized M(X) Drug-resistant TB Treatment Strategy Study Phase 4
Completed NCT03338621 - Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Phase 2/Phase 3
Not yet recruiting NCT05007795 - Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis N/A
Completed NCT03728725 - Xpert MTB/XDR Clinical Evaluation Trial
Completed NCT02589782 - Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Phase 2/Phase 3
Recruiting NCT02619994 - Treatment Shortening of MDR-TB Using Existing and New Drugs Phase 2
Completed NCT01918397 - Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Phase 2